Impact of lamivudine-based antiretroviral treatment on hepatitis B viremia in HIV-coinfected South Africans

Show simple item record

dc.contributor.author Lukhwareni, Azwidowi
dc.contributor.author Gededzha, Maemu Petronella
dc.contributor.author Amponsah-Dacosta, Edina
dc.contributor.author Blackard, Jason T.
dc.contributor.author Burnett, Rosemary J.
dc.contributor.author Selabe, Selokela Gloria
dc.contributor.author Kyaw, Thanda
dc.contributor.author Mphahlele, M. Jeffrey
dc.date.accessioned 2021-02-15T09:39:41Z
dc.date.available 2021-02-15T09:39:41Z
dc.date.issued 2020-06
dc.description.abstract This prospective study investigated the impact of lamivudine-containing antiretroviral therapy (ART) on HIV-positive patients in South Africa with baseline hepatitis B virus (HBV) infection. Follow-up samples from 56 HBV/HIV co-infected patients, 25 with occult HBV infection (OBI) and 31 with chronic HBV infection (CHB), were available for analysis. HBV viral loads were quantified at 6, 12, 18, and 24 months post-ART initiation by the COBAS TaqMan HBV Test 48 assay, and the HBV polymerase gene was amplified with an in-house nested polymerase chain reaction assay. During 24 months of lamivudine-based ART, 6 of 8 (75%) OBI and 4 of 6 (67%) CHB patients achieved undetectable levels of HBV DNA, while 2 patients had persistent HBV DNA levels 2 105 despite lamivudine-based ART for 24 months. HIV viremia was undetectable in all patients at 12 months, suggesting high adherence to ART. Several lamivudine-associated HBV resistance mutations, including L180M, A181T, M204I, and M204V, were observed. Sequence analysis also revealed a rare genotype G infection. While resource-limited settings may use lamivudine-based ART because of availability and low cost, antivirals with dual therapy against HBV and HIV (e.g., lamivudine and tenofovir) should always be recommended with the regular monitoring of HBV viremia levels. en_ZA
dc.description.department Medical Virology en_ZA
dc.description.librarian am2021 en_ZA
dc.description.sponsorship The South African National Research Foundation, Poliomyelitis Research Foundation, Stella and Paul Lowenstein Trust, and Canon and Collins scholarship. en_ZA
dc.description.uri http://www.mdpi.com/journal/viruses en_ZA
dc.identifier.citation Lukhwareni, A., Gedezha, M.P., Amponsah-Dacosta, E. et al. 2020, 'Impact of lamivudine-based antiretroviral treatment on hepatitis B viremia in HIV-coinfected South Africans', Vruses, vol. 12, no. 6, art. 634, pp. 1-13. en_ZA
dc.identifier.issn 1999-4915 (online)
dc.identifier.other 10.3390/v12060634
dc.identifier.uri http://hdl.handle.net/2263/78613
dc.language.iso en en_ZA
dc.publisher MDPI Publishing en_ZA
dc.rights © 2020 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. en_ZA
dc.subject Lamivudine en_ZA
dc.subject Antiretroviral therapy (ART) en_ZA
dc.subject Hepatitis B virus (HBV) en_ZA
dc.subject HIV coinfection en_ZA
dc.subject Human immunodeficiency virus (HIV) en_ZA
dc.title Impact of lamivudine-based antiretroviral treatment on hepatitis B viremia in HIV-coinfected South Africans en_ZA
dc.type Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record